DURHAM, N.C. – Scientists at Duke Health have uncovered a powerful mechanism for generating durable immunity against breast cancer, based on an unusual finding: a small cohort of women who received an experimental breast cancer vaccine over two decades ago are still alive today, a survival rate considered unheard of for patients with advanced, metastatic disease. The key to their long-term survival lies in a specific immune memory marker that, when targeted, can dramatically boost the vaccine’s effectiveness.
The 20-Year Survival Enigma
The new investigation centered on patients from an early-stage clinical trial led by Herbert Kim Lyerly, M.D., George Barth Geller Distinguished Professor of Immunology at Duke University School of Medicine. The vaccine, administered more than 20 years ago, was initially viewed as a potential therapy that hadn’t fully delivered on its promise. However, the unexpected, decades-long survival of a subset of participants prompted researchers to re-examine their immune profiles.
Zachary Hartman, Ph.D., senior author of the study and Associate Professor at Duke University School of Medicine, and his team studied the patients’ immune systems and were “stunned” to discover that they still maintained a robust population of strong, long-lasting immune cells that actively recognized and targeted their cancer.
The Crucial Role of CD27
The most critical finding was that these persistent immune cells carried a special marker called CD27. This molecule is essential for helping the immune system form long-term immune memory, allowing it to “remember” a threat—like cancer—and fight it off years after the initial exposure. The findings suggested that if researchers could strategically activate or “boost” the CD27-mediated response, they could potentially unlock the full anti-cancer potential of vaccines.
Supercharging the Anti-Tumor Response
To test this, the research team developed a combination approach. They paired a vaccine targeting the HER2 protein (which is overexpressed on the surface of some breast cancer cells) with a CD27-targeting stimulatory antibody in various mouse models. The results demonstrated a clear path to enhanced efficacy:
-
The vaccine administered alone resulted in complete tumor regression in only about six percent of the mice.
-
By combining the vaccine with the CD27-targeting antibody, the rate of complete tumor regression soared to nearly forty percent.
-
In a subsequent, highly potent combination, the researchers added a different antibody to specifically stimulate CD8+ T cells (the traditional “killer” immune cells). This three-pronged approach achieved complete tumor rejection in nearly ninety percent of the mice.
The Shift to Helper Cells (CD4+ T Cells)
The mechanism behind the success hinged on a change in focus. While most cancer immunotherapy research targets the CD8+ “killer” T cells, the Duke study indicated that the CD27 antibody worked primarily by supercharging CD4+ T cells, often referred to as “helper” cells.
This research highlights that CD4+ T cells are not merely supportive actors; they play a starring role by driving the essential long-term immune memory and helping other immune cells, including the CD8+ cells, perform their function more effectively. Dr. Hartman noted that this study fundamentally shifts our thinking regarding the cell types most essential for durable, truly effective anti-tumor responses.
A One-Time, Combinatorial Advantage
Another significant implication for clinical translation is the simplicity of the approach. The team found that the CD27-targeting antibody only needed to be administered once, concurrently with the vaccine, to produce a lasting effect. This characteristic suggests the strategy could be easily and effectively integrated with currently available cancer treatments, including immune checkpoint inhibitors and antibody-drug conjugates already in use for patients. The study provides a crucial “missing piece of the puzzle” for realizing the full therapeutic promise of cancer vaccines.
Reference:
Duke Health. Could a Cancer Vaccine Developed Long Ago Hold the Key to Long-Term Survival? (https://corporate.dukehealth.org/news/could-cancer-vaccine-developed-long-ago-hold-key-long-term-survival)
